Analyst Price Target is €467.00
▲ +44.36% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Sartorius Stedim Biotech in the last 3 months. The average price target is €467.00, with a high forecast of €470.00 and a low forecast of €464.00. The average price target represents a 44.36% upside from the last price of €323.50.
Current Consensus is
The current consensus among 0 investment analysts is to n/a stock in Sartorius Stedim Biotech. This rating has held steady since January 2022, when it changed from a Buy consensus rating.
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.